| Offering Information |
| Expected Date | WITHDRAWN |
| Proposed Exchange/Ticker |
Nasdaq: ITCA |
| Security Type |
Common Stock |
| Lead Underwriter |
Credit Suisse First Boston |
| Days In Registration |
227 |
| Date Filed |
7-Feb-2005 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2007) |
| Industry |
Manufacturing |
| Business Description |
Specialize in developing and systematically generating new uses for clinical-stage drugs purchased or licensed from major pharmaceutical companies |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
24.65M |
| Contact |
- |
| Number of Employees |
16 |
|
| Original Filing Information |
| US |
| Shares Filed |
5.0M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
- |
| · As a Percent |
- |
| Overallotment Shares Filed |
750.0K |
| File Amount |
- |
| File Price Range |
$14.00 - $12.00 |
| File Mid Price |
$13.00 |
|
